Imipenem and ciprofloxacin consumption as factors associated with high incidence rates of resistant Pseudomonas aeruginosa in hospitals in northern France

Journal of Hospital Infection

Volumn 77, Issue 4, 2011, Pages 343-347

  Miliani, K ^a   L'Heriteau F ^a   Lacave L ^a   Carbonne, A ^a   Astagneau, P ^a,b  

^a Regional Coordinating Centre for Nosocomial Infection Control (C CLIN Paris Nord)   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Antimicrobial resistance; Ciprofloxacin consumption; France; Hospital antimicrobial consumption; Imipenem consumption; Resistant P. aeruginosa

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; IMIDAZOLE DERIVATIVE; IMIPENEM; MACROLIDE; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DRUG USE; FRANCE; HEALTH CARE FACILITY; HEALTH CARE PERSONNEL; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; MULTIVARIATE ANALYSIS; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUALITY CONTROL; RISK FACTOR; UNIVARIATE ANALYSIS;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; FRANCE; HOSPITALS; HUMANS; IMIPENEM; INCIDENCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 79952706235     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhin.2010.11.024     Document Type: Article

References (24)

1. Thiolet J.-M., Lacavé L., Jarno P., et al. Prévalence des infections nosocomiales, France, 2006. Bull Epidemiol Hebd 2007, 51-52:429-432.
2. Strateva T., Yordanov D. Pseudomonas aeruginosa - a phenomenon of bacterial resistance. J Med Microbiol 2009, 58:1133-1148.
3. Mesaros N., Nordmann P., Plesiat P., et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 2007, 13:560-578.
4. Aloush V., Navon-Venezia S., Seigman-Igra Y., Cabili S., Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006, 50:43-48.
5. Lautenbach E., Synnestvedt M., Weiner M.G., et al. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol 2010, 31:47-53.
6. Mutnick A.H., Rhomberg P.R., Sader H.S., Jones R.N. Antimicrobial usage and resistance trend relationships from the MYSTIC programme in North America (1999-2001). J Antimicrob Chemother 2004, 53:290-296.
7. Fridkin S.K., Hill H.A., Volkova N.V., et al. Temporal changes in prevalence of antimicrobial resistance in 23 U.S. hospitals. Emerg Infect Dis 2002, 8:697-701.
8. Rogues A.M., Dumartin C., Amadeo B., et al. Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals. Infect Control Hosp Epidemiol 2007, 28:1389-1395.
9. Miliani K., L'Heriteau F., Alfandari S., et al. Specific control measures for antibiotic prescription are related to lower consumption in hospitals: results from a French multicentre pilot study. J Antimicrob Chemother 2008, 62:823-829.
10. Carlet J., Astagneau P., Brun-Buisson C., et al. French national program for prevention of healthcare-associated infections and antimicrobial resistance, 1992-2008: positive trends, but perseverance needed. Infect Control Hosp Epidemiol 2009, 30:737-745.
11. Members of the SFM Antibiogram Committee Comité de l'antibiogramme de la société française de microbiologie report 2003. Int J Antimicrob Agents 2003, 21:364-391.
12. Carmeli Y., Troillet N., Eliopoulos G.M., Samore M.H. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999, 43:1379-1382.
13. Lepper P.M., Grusa E., Reichl H., Hogel J., Trautmann M. Consumption of imipenem correlates with beta-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002, 46:2920-2925.
14. Mohr J.F., Jones A., Ostrosky-Zeichner L., Wanger A., Tillotson G. Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university-affiliated teaching hospital: an 8-year-experience: 1995-2002. Int J Antimicrob Agents 2004, 24:346-351.
15. Kang C.I., Kim S.H., Park W.B., et al. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist 2005, 11:68-74.
16. Zervos M.J., Hershberger E., Nicolau D.P., et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 2003, 37:1643-1648.
17. Bhavnani S.M., Callen W.A., Forrest A., et al. Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. Hospitals. Am J Health Syst Pharm 2003, 60:1962-1970.
18. Grammatico-Guillon L., Thiolet J.M., Bernillon P., Coignard B., Khoshnood B., Desenclos J.C. Relationship between the prevalence of meticillin-resistant Staphylococcus aureus infection and indicators of nosocomial infection control measures: a population-based study in French hospitals. Infect Control Hosp Epidemiol 2009, 30:861-869.
19. Johnson J.K., Smith G., Lee M.S., et al. The role of patient-to-patient transmission in the acquisition of imipenem-resistant Pseudomonas aeruginosa colonization in the intensive care unit. J Infect Dis 2009, 200:900-905.
20. Lepelletier D., Cady A., Caroff N., et al. Imipenem-resistant Pseudomonas aeruginosa gastrointestinal carriage among hospitalized patients: risk factors and resistance mechanisms. Diagn Microbiol Infect Dis 2010, 66:1-6.
21. Steinke D., Davey P. Association between antibiotic resistance and community prescribing: a critical review of bias and confounding in published studies. Clin Infect Dis 2001, 33(Suppl. 3):S193-S205.
22. White R.L., Friedrich L.V., Mihm L.B., Bosso J.A. Assessment of the relationship between antimicrobial usage and susceptibility: differences between the hospital and specific patient-care areas. Clin Infect Dis 2000, 31:16-23.
23. Pitten F.A., Panzig B., Schroder G., Tietze K., Kramer A. Transmission of a multiresistant Pseudomonas aeruginosa strain at a German university hospital. J Hosp Infect 2001, 47:125-130.
24. Bert F., Maubec E., Bruneau B., Berry P., Lambert-Zechovsky N. Multi-resistant Pseudomonas aeruginosa outbreak associated with contaminated tap water in a neurosurgery intensive care unit. J Hosp Infect 1998, 39:53-62.